Timber Creek Capital Management LLC Has $4.08 Million Stake in AstraZeneca PLC (NASDAQ:AZN)

Timber Creek Capital Management LLC reduced its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 1.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 62,275 shares of the company’s stock after selling 952 shares during the quarter. Timber Creek Capital Management LLC’s holdings in AstraZeneca were worth $4,080,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP acquired a new stake in AstraZeneca in the 3rd quarter valued at about $28,000. Albion Financial Group UT lifted its position in shares of AstraZeneca by 68.9% in the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after buying an additional 248 shares during the last quarter. Groupama Asset Managment boosted its stake in shares of AstraZeneca by 22.9% during the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after acquiring an additional 101,225 shares during the period. Ashton Thomas Securities LLC bought a new position in shares of AstraZeneca during the 3rd quarter worth approximately $45,000. Finally, Versant Capital Management Inc increased its holdings in shares of AstraZeneca by 2,618.5% during the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock worth $48,000 after acquiring an additional 707 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Morgan Stanley initiated coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They set an “overweight” rating for the company. Finally, UBS Group raised shares of AstraZeneca from a “neutral” rating to a “buy” rating in a report on Thursday, February 13th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Trading Up 1.7 %

AZN opened at $74.80 on Wednesday. The company has a 50-day simple moving average of $68.32 and a 200 day simple moving average of $73.29. AstraZeneca PLC has a twelve month low of $62.75 and a twelve month high of $87.68. The company has a quick ratio of 0.74, a current ratio of 0.93 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $231.95 billion, a price-to-earnings ratio of 33.10, a P/E/G ratio of 1.41 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. Analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Monday, March 24th. Shareholders of record on Friday, February 21st will be paid a dividend of $1.03 per share. This is an increase from AstraZeneca’s previous semi-annual dividend of $0.49. The ex-dividend date is Friday, February 21st. This represents a yield of 2%. AstraZeneca’s payout ratio is presently 43.36%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.